10-Q/A: GT Biopharma Restates Q3 2025 Financials, Cites Accounting Error

GT Biopharma, Inc. has filed an amended quarterly report for Q3 2025 to correct material errors related to Greenshoe Rights liability classification, while reporting a wider net loss for the nine months ended September 30, 2025.

Summary

• GT Biopharma, Inc. (GTBP) filed a Form 10-Q/A to restate its financial statements for the quarter ended September 30, 2025, due to material errors in classifying Greenshoe Rights as a liability.
• The restatement resulted in a net income of $8,299,000 for the three months ended September 30, 2025, compared to a previously reported net loss of $(3,114,000).
• For the nine months ended September 30, 2025, the restatement led to a net loss of $(22,646,000), a significant increase from the previously reported net loss of $(5,323,000).
• The company's disclosure controls and procedures were deemed ineffective as of September 30, 2025, due to the identified accounting errors, constituting a material weakness in internal control over financial reporting.
• GTBP continues to operate as a clinical-stage biopharmaceutical company focused on its TriKE and Dual Targeting TriKE platforms for immuno-oncology.
• Research and development expenses decreased by 46% to $2,096,000 for the nine months ended September 30, 2025, compared to $3,868,000 in the prior year period.
• Selling, general, and administrative expenses decreased by 33% to $4,731,000 for the nine months ended September 30, 2025, compared to $6,733,000 in the prior year period, primarily due to reduced legal fees.
• Net cash used in operating activities improved to $(8,893,000) for the nine months ended September 30, 2025, from $(10,436,000) in the prior year period.
• The company raised $7,470,000 in net cash from financing activities for the nine months ended September 30, 2025, including proceeds from Series L Convertible Preferred Stock and warrant exercises.
• GTBP regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on June 13, 2025.
• Substantial doubt about the company's ability to continue as a going concern within one year remains, as it has sustained operating losses since inception and has no approved products for sale.
• Ongoing legal proceedings include disputes with a former CFO (Ohri Matter) and multiple claims related to convertible notes (TWF Global, Silberfein, DiPietro, and Werthman Trust Matters), with plaintiffs seeking significant damages.
• The company's product pipeline includes GTB-3650 (IND cleared, clinical study enrollment started Jan 21, 2025), GTB-5550 (IND submission anticipated late Dec 2025 or Jan 2026), and GTB-7550 (in early development for autoimmune disorders).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the significant restatement, ongoing material weakness in internal controls, and the explicit 'going concern' warning, despite some improvements in cash burn and equity position. The legal challenges and potential for further dilution also weigh heavily.

Positives

• Net cash used in operating activities decreased to $8.9 million for the nine months ended September 30, 2025, from $10.4 million in the prior year, indicating improved operational cash burn.
• Total current liabilities significantly decreased to $1,321,000 as of September 30, 2025, from $5,902,000 as of December 31, 2024.
• Stockholders' Equity (Deficit) improved substantially to $3,000,000 as of September 30, 2025, from a deficit of $(1,670,000) as of December 31, 2024.
• Research and development expenses decreased by 46% ($1.8 million) for the nine months ended September 30, 2025, compared to the prior year, reflecting resource optimization.
• Selling, general, and administrative expenses decreased by 33% ($2.2 million) for the nine months ended September 30, 2025, primarily due to reduced legal fees and other cost-reduction measures.
• The company successfully raised $7.5 million in net cash from financing activities during the nine months ended September 30, 2025.
• GTBP regained compliance with the Nasdaq Minimum Stockholders Equity Requirement on June 13, 2025.
• The IND application for GTB-3650, a next-generation camelid nanobody TriKE, was cleared by the FDA in late June 2024, and study enrollment began on January 21, 2025.
• The company initiated a GMP manufacturing campaign for GTB-5550, with an IND submission anticipated in late December 2025 or January 2026.

Negatives

• The company reported a restated net loss of $(22,646,000) for the nine months ended September 30, 2025, significantly wider than the $(9,387,000) loss in the prior year period.
• Disclosure controls and procedures were deemed ineffective as of September 30, 2025, due to material errors in accounting for complex financial transactions, specifically Greenshoe Rights liability.
• A material weakness in internal control over financial reporting was identified regarding the proper application of ASC 480 for complex financial transactions.
• Substantial doubt exists about the company's ability to continue as a going concern within one year, as it has no approved products and continues to incur operating losses.
• Cash and cash equivalents decreased to $2,528,000 as of September 30, 2025, from $3,951,000 as of December 31, 2024.
• Interest income decreased by 69% to $106,000 for the nine months ended September 30, 2025, compared to $343,000 in the prior year period.
• The company recognized a significant non-cash loss on initial recognition of Greenshoe Rights liability of $(28,736,000) for the nine months ended September 30, 2025.
• Multiple legal proceedings are ongoing, including claims from a former CFO and several convertible noteholders, with potential damages exceeding $500,000 in some cases.
• The conversion price of Series L 10% Convertible Preferred Stock was decreased from $2.043 to $0.6421 due to dilutive issuances, and further to $0.5319 in October 2025, indicating significant dilution for existing shareholders.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to sustained operating losses and no product sales.
• Inability to secure additional financing on acceptable terms, which could force delays, reductions, or elimination of discretionary spending, adversely affecting business prospects and operations.
• Ineffective disclosure controls and procedures and a material weakness in internal control over financial reporting, increasing the risk of future financial misstatements.
• Potential adverse outcomes from ongoing legal proceedings, including the Ohri Matter and multiple convertible note disputes, which could result in significant damages and divert management attention.
• Risk of delisting from Nasdaq if the company fails to maintain compliance with listing requirements, which could negatively impact capital raising, liquidity, and share price.
• The company's reliance on its TriKE and Dual Targeting TriKE platforms, with no product candidates currently approved for sale, introduces significant development and commercialization risks.
• The full-ratchet price and anti-dilution protections on Series L Preferred Stock and Warrants could lead to substantial future dilution for common stockholders.
• Dependence on third-party agreements for research, development, and manufacturing services (e.g., Cytovance Biologics, University of Minnesota).

Future Outlook

The company anticipates submitting an IND application for GTB-5550 in late December 2025 or January 2026. It expects to continue incurring operating losses into the foreseeable future and believes existing cash resources will not be sufficient to fund anticipated operations for one year without additional financing. The company will continue to monitor its compliance with Nasdaq's Minimum Stockholders Equity Requirement.

Management Comments

• "We believe if it is unable to obtain additional financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed financial statements are issued."
• "There can be no assurances that the Company will be able to secure additional financing on acceptable terms."
• "In the event the Company does not secure additional financing, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company’s business prospects, ability to meet long-term liquidity needs and the ability to continue operations."
• "Management determined that this control deficiency constituted a material weakness in internal control over financial reporting as of June 30, 2025, and September 30, 2025."
• "Subsequent to September 30, 2025, the Company adopted additional internal controls wherein if the issuance of stock purchase rights or other derivative financial instruments, or any other complex transaction is contemplated, an accounting consultant will be engaged as to the financial statement impact that any such transaction may have, prior to consummation of the transaction."

Industry Context

StockSavvy.ai notes that GT Biopharma operates in the highly competitive and capital-intensive immuno-oncology sector, focusing on its proprietary TriKE and Dual Targeting TriKE platforms. The shift to camelid nanobody technology for next-generation candidates like GTB-3650 and GTB-5550 reflects an industry trend towards optimizing antibody engineering for enhanced potency and stability. The company's ongoing clinical trials for AML/MDS and anticipated IND for solid tumors position it against numerous established and emerging biopharma players in these therapeutic areas. The significant R&D and SG&A cost reductions, while improving cash burn, could also signal a more constrained operational environment compared to peers with larger funding bases, especially given the 'going concern' warning.

Comparison to Industry Standards

• GT Biopharma's TriKE platform, which activates NK cells, is a differentiated approach compared to many T-cell focused immunotherapies. While T-cell therapies like CAR-T (e.g., Novartis' Kymriah, Gilead's Yescarta) have shown high efficacy, they are often associated with severe cytokine release syndrome (CRS) and neurotoxicity. GTBP's preclinical data suggesting less CRS and fewer neurological complications with TriKEs could offer a safety advantage, a critical factor in oncology.
• The transition from GTB-3550 to GTB-3650, incorporating camelid nanobody technology, aligns with broader industry efforts to improve antibody affinity and production yields. Companies like Ablynx (now Sanofi) have pioneered nanobody development, demonstrating their potential for enhanced target binding and stability. GTBP's preclinical data showing 'markedly enhanced potency' for GTB-3650 over GTB-3550 suggests a competitive improvement in their core technology.
• The company's net loss of $(22.6) million for the nine months ended September 30, 2025, and ongoing 'going concern' warning, contrast sharply with more mature biopharmaceutical companies that have approved products and positive cash flows. Even for clinical-stage biotechs, a persistent going concern warning and reliance on frequent capital raises can be a red flag, indicating a higher risk profile compared to peers with stronger balance sheets or more advanced pipelines nearing commercialization.
• The decrease in R&D expenses by 46% and SG&A by 33% for the nine months ended September 30, 2025, while positive for cash burn, could also imply a slowdown in the pace of development or a more conservative approach to spending, potentially impacting the speed at which new candidates advance through the clinic compared to well-funded competitors aggressively pursuing multiple programs.

Management Changes

Corporate Governance

Legal Proceedings

• **Ohri Matter**: Company filed an AAA Arbitration Demand against former CFO Manu Ohri on July 22, 2024, for breach of fiduciary duties and contract. Mr. Ohri filed counterclaims on September 3, 2024. The final hearing was postponed indefinitely for mediation, with a status conference scheduled for December 11, 2025. The company cannot determine the probability of outcome or range of losses.
• **TWF Global Matter**: TWF Global, LLC filed a complaint on May 24, 2023, alleging breach of convertible notes. After initial dismissal, Z-One, LLC (another party) filed a new summons on February 17, 2025, and a complaint on June 25, 2025, alleging breach of a $150,000 convertible note and seeking damages over $500,000. The company filed a motion to dismiss on August 26, 2025, believing the claims are without merit.
• **Silberfein, DiPietro, and Werthman Trust Matters**: Three separate summonses were filed on July 8-9, 2025, alleging breach of convertible notes (principal amounts of $100,000, $100,000, and $150,000 respectively) and seeking damages over $500,000 each. The company intends to seek dismissal, believing the claims are without merit.

Related Party Transactions

• **Cytovance Biologics, Inc.**: Accounts payable to Cytovance, a related party (owns >5% common stock), decreased from $1,183,000 at December 31, 2024, to $60,000 at September 30, 2025. R&D expenses recognized were $686,000 for 9M 2025 (vs. $1.4 million for 9M 2024). The company issued pre-funded warrants ($847,000 fair value) in March 2025 and common stock ($810,000 fair value in 2024) to settle payables.
• **University of Minnesota**: The 2023 Sponsored Research Agreement (effective July 1, 2023, expiring December 31, 2025) involves payments totaling $1.9 million. R&D expenses recognized were $647,000 for 9M 2025 (vs. $863,000 for 9M 2024). Commitments for unbilled services amounted to $216,000 as of September 30, 2025. The 2016 Exclusive Patent License Agreement and 2021 Exclusive License Agreement also involve royalty and milestone payments.
• **PDPC Advisors Inc.**: On June 30, 2025, the company entered into an Advisory Agreement for $100,000 cash payments and issued a pre-funded warrant (fair value $537,000) to PDPC, whose CEO has >5% beneficial ownership.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk due to full-ratchet anti-dilution protections on Series L Preferred Stock and Warrants, as evidenced by conversion price reductions. The 'going concern' warning and material weakness in internal controls pose substantial investment risk. However, the improvement in stockholders' equity and Nasdaq compliance are positive for investor confidence.
• **Employees**: Stock option awards for management and non-employee directors indicate continued incentive alignment, but the overall financial instability and potential for reduced discretionary spending could impact job security or future compensation.
• **Customers/Patients**: Continued development of TriKE product candidates (GTB-3650, GTB-5550, GTB-7550) offers potential future therapeutic options for various cancers and autoimmune disorders, but the company's financial challenges could delay or halt these programs.
• **Suppliers/Creditors**: Cytovance Biologics, Inc. and the University of Minnesota are significant creditors and partners. The reduction in accounts payable to Cytovance is positive, but ongoing commitments and the company's liquidity concerns could affect future payment reliability.
• **Regulatory Authorities (FDA/Nasdaq)**: The FDA has cleared the IND for GTB-3650, indicating progress. Nasdaq compliance has been regained, but continued monitoring means ongoing scrutiny. The SEC is involved through the restatement and disclosure requirements.

Next Steps

• Continue clinical study enrollment for GTB-3650 for relapsed/refractory AML and high-grade MDS.
• Advance GTB-5550 through preclinical studies and GMP manufacturing.
• Anticipate submission of an IND application for GTB-5550 in late December 2025 or January 2026.
• Explore and assess potential manufacturers for GTB-7550.
• Address the identified material weakness in internal control over financial reporting by engaging accounting consultants for complex financial transactions.
• Participate in a status conference for the Ohri Matter on December 11, 2025.
• Vigorously defend against claims in the TWF Global, Silberfein, DiPietro, and Werthman Trust legal matters.
• Seek additional financing to fund anticipated operations beyond one year.

Key Dates

Recommendation

A seasoned investor or institution would likely issue a 'strong sell' recommendation. The restatement of financials due to material accounting errors, coupled with the explicit 'going concern' warning from both management and auditors, signals severe financial distress and operational control deficiencies. While there are some positive developments like reduced cash burn and Nasdaq compliance, these are overshadowed by a widening net loss, significant ongoing legal challenges, and the high risk of further shareholder dilution from anti-dilution provisions. The company's reliance on future financing in a challenging environment, without any approved products, makes it a highly speculative and risky investment.

Keywords

Biopharma, Immuno-oncology, TriKE, GTB-3650, GTB-5550, SEC Filing, 10-Q/A, Restatement, Going Concern, Clinical Stage, Warrant Liability, Greenshoe Rights, Nasdaq Compliance, AML, MDS, Solid Tumors, Autoimmune Disorders, CD33, B7-H3, NK Cells